Home / Health / ADHD Drug Shortage Hits Japan: New Patients Denied
ADHD Drug Shortage Hits Japan: New Patients Denied
31 Mar
Summary
- Japan faces a critical shortage of the ADHD medication Concerta.
- New prescriptions for Concerta have been temporarily halted.
- Increased awareness of adult ADHD has driven demand, worsening the shortage.
A significant shortage of Concerta, the primary ADHD medication in Japan, has led to a halt in new prescriptions, leaving patients without essential treatment. Doctors are unable to prescribe the drug due to supply chain issues.
The scarcity is largely attributed to an imbalance between supply and demand. Increased public and medical awareness of adult ADHD has led to a dramatic rise in diagnoses, with new diagnoses in adults over 20 increasing significantly since 2010. This surge in demand has outpaced Concerta's availability.
Adding to the challenge, the medication's manufacturer, Janssen Pharmaceutical K.K., announced supply limitations starting in late September 2025, which have persisted longer than initially projected. The company has stated it cannot predict when supply will recover, advising patients to consult healthcare providers for interim solutions.
This situation is critically affecting many individuals who rely on Concerta for managing their ADHD symptoms. Experts urge swift action from the government and the pharmaceutical company to address the ongoing crisis.
